97270 ā
Immunoglobulins specific features characterized by post-translational modification Glycosylation, sialylation, or fucosylation
GLYCOSYLATED ANTIBODIES
#2Antigen Binding Proteins
#3CDCP1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#4CD161 BINDING PROTEINS AND RELATED METHODS
#5ANTI-CCR8 MONOCLONAL ANTIBODIES AND THEIR THERAPEUTIC USE
#6ANTIBODIES BINDING B7-H3 AND USES THEREOF
#7ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF
#8PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN
#9IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOF
#10CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE
#11ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF
#12SMAGP FUSION MOLECULES AND METHODS OF USE THEREOF
#13Anti-Inflammatory Polypeptides
#14ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE
#15ANTI-CCR8 ANTIBODIES AND USES THEREOF
#16ANTI-FGFR2 ANTIBODIES IN COMBINATION WITH CHEMOTHERAPY AGENTS IN CANCER TREATMENT
#17ANTI-B7H3 ANTIBODIES AND METHODS OF USE
#18BISPECIFIC HER2 AND CD3 BINDING MOLECULES
#19MULTI-DOMAIN BINDING MOLECULES
#20ANTIBODIES TARGETING C-KIT AND/OR SIGLEC AND USES THEREOF
#21COMMERCIAL-SCALE RECOMBINANT PROTEIN PRODUCTION IN RAT HYBRIDOMA CELLS
#22POPULATION OF ANTIBODIES COMPRISING HOMOGENEOUS ANTIBODIES EACH HAVING LEFT-RIGHT ASYMMETRIC SUGAR CHAINS, AND METHOD FOR PRODUCING SAME
#23DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
#24GLYCOENGINEERED POLYPEPTIDES TARGETING IMMUNOGLOBULIN A AND COMPLEXES COMPRISING THE SAME
#25TETRAVALENT MULTISPECIFIC ANTIBODIES
#26ANTI-CTLA4 ANTIBODIES FOR TREATMENT OF KRAS MUTANT CANCERS
#27METHODS OF MAKING FUCOSYLATED AND AFUCOSYLATED FORMS OF A PROTEIN
#28Modified IgG1 Fc Domains and Anti-CD40 Domain Antibody Fusions Therewith
#29ANTIBODIES TO CD70
#30ANTI-TREM2 ANTIBODIES AND RELATED METHODS
#31METHODS OF TREATING SARCOIDOSIS WITH A TNF-A ANTIBODY AND ASSOCIATED COMPOSITIONS AND METHODS
#32ANTIGEN-BINDING MOLECULE FOR PROMOTING ELIMINATION OF ANTIGENS
#33METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#34RECOMBINANT OLIGOSACCHARYLTRANSFERASES AND METHODS OF USE THEREOF
#35Method for Producing Spesolimab
#36PLANT-PRODUCED mABs AGAINST CHIKUNGUNYA VIRUS WITH ENHANCED EFFECTOR FUNCTION AND EFFICACY
#37SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME
#38DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
#39Dosing Regimen for Therapies Comprising Bispecific Anti-EGFR/C-Met Antibodes
#40ANTI-PDL1 ANTIBODY FORMULATIONS
#41ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS
#42METHODS OF PRODUCING ANTI-CD19 ANTIBODIES
#43METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
#44Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
#45Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)
#46COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY
#47ANTIBODY MOLECULES
#48ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME
#49Methods of Treating IL1RAP Associated Cancers with Anti Human Interleukin-1 Receptor Accessory Protein (IL1 RAP) Antibodies
#50ENGINEERED GLYCOPROTEIN POPULATION AND USES THEREOF
#51ENGINEERED GLYCOPROTEIN POPULATION AND USES THEREOF
#52PLANT-DERIVED THERAPEUTIC MONOCLONAL ANTIBODIES AND THEIR USE IN PREGNANT WOMEN
#53RISANKIZUMAB COMPOSITIONS
#54ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES
#55ANTI-PVRIG ANTIBODIES AND METHODS OF USE
#56ANTIBODIES AGAINST TIM3 AND USES THEREOF
#57TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab
#58GLYCOENGINEERED ANTIBODIES
#59RISANKIZUMAB COMPOSITIONS
#60MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE
#61HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 1 (SARS-CoV-1)
#62NEUTRALIZING MONOCLONAL ANTIBODIES TO BK VIRUS
#63ANTIBODIES WITH NOVEL FC MODIFICATION COMBINATIONS THAT INCREASE ANTIBODY FUNCTION
#64THERAPEUTIC ANTIBODIES
#65ENGINEERED POLYPEPTIDES
#66THERAPEUTIC AND DIAGNOSTIC AGENTS AND USES THEREOF
#67ANTI-CCR8 ANTIBODIES AND USES THEREOF
#68GLYCAN-MEDIATED PROTEIN DEGRADATION
#69ANTI-CD30 ANTIBODIES AND METHODS FOR TREATING CD30+ CANCER
#70ANTI-FGFR2 ADCC ENHANCED ANTIBODY AND USE THEREOF
#71MULTIFUNCTIONAL BISPECIFIC FUSION POLYPEPTIDE
#72HUMAN MONOCLONAL ANTIBODIES TO EASTERN EQUINE ENCEPHALITIS VIRUS AND USES THEREFOR
#73KLRB1 BINDING AGENTS AND METHODS OF USE THEREOF
#74Afucosylated Anti-FGFR2IIIB Antibodies
#75Combination Therapies for Treating Cancer
#76MULTIFUNCTIONAL ANTIBODIES
#77ANTI-MUC1 ANTIBODY
#78DEGRADATION OF SURFACE PROTEINS USING DUAL BINDING AGENT
#79ANTIBODIES THAT BIND TO OX40 AND THEIR USES
#80High Concentratioin Anti-BLYS Pharmaceutical Formulations
#81TREATMENT OF SOLID TUMORS
#82ANTI-PSMA ANTIBODIES, VARIANTS, AND USES THEREOF
#83COMPOSITIONS AND METHODS FOR TREATING CANCER
#84ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS
#85BIOSYNTHETIC BIOPARATOPIC OR BISPECIFIC BINDING MOLECULES WITH ENHANCED EFFECTOR FUNCTIONS
#86TREATMENT FOR ACUTE MYELOID LEUKEMIA WITH ANTI-CD70 ANTIBODIES
#87ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
#88Production of Biosimilar Ustekinumab In CHO Cells
#89OPTIMIZING POLYPEPTIDE SIALIC ACID CONTENT
#90PLATFORM TECHNOLOGY FOR BISPECIFIC ANTIGENBINDING PROTEINS
#91POLYNUCLEOTIDES ENCODING ANTIBODIES WHICH BIND THE EC3 DOMAIN OF CADHERIN-6 (CDH6) AND POSSESS INTERNALIZATION ABILITY
#92ANTI-MUC1 ANTIBODY-DRUG CONJUGATE
#93FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT
#94MONOCLONAL ANTIBODIES AND BISPECIFIC ANTIBODY AGAINST C-MET
#95ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF
#96Anti-FGFR2b Antibodies, Conjugates and Methods of Use
#97ANTI-CD39 ANTIBODY
#98COMPOSITIONS AND METHODS FOR TREATING IMMUNE THROMBOCYTOPENIA
#99COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#100DE-N-ACETYLATED POLYSIALIC ACID (dPSA) BINDING AGENT AND METHOD OF USING SAME
#101NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERING
#102TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE
#103GLYCOSYLATED FC VARIANTS WITH IMPROVED SELECTIVE BINDING AFFINITY TO FCyRIIIA
#104ANTIBODY COMPOSITIONS FOR DISRUPTING BIOFILMS
#105ANTI GLUCOCORTICOID-INDUCED TNFR-RELATED (GITR) PROTEIN ANTIBODIES AND USES THEREOF
#106ANTI-TREM1 ANTIBODIES AND RELATED METHODS
#107MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF
#108COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
#109DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
#110RADIOLABELING OF POLYPEPTIDES
#111Early Detection Of Hepatocellular Carcinoma
#112GLYCOSYLATED FORM OF ANTI-IL13R ANTIBODY
#113TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER
#114METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#115Anti-cMET Antibodies and Methods of Use
#116ANTI-PDL1 ANTIBODY FORMULATIONS
#117ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS
#118NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS
#119ANTI-HUMAN ATP6V1B2 ANTIBODIES AND USES THEREOF
#120ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF
#121DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
#122BISPECIFIC ANTIGEN BINDING CONSTRUCTS TARGETING HER2
#123Anti-Polyubiquitin Multispecific Antibodies
#124ANTI-CCR8 ANTIBODIES AND METHODS OF USE
#125ANTI-ILT2 ANTIBODIES AND USES THEREOF
#126COMBINATION THERAPY OF ANTI-TYRP1/ANTI-CD3 BISPECIFIC ANTIBODIES AND TYRP1-SPECIFIC ANTIBODIES
#127ANTIBODY MOLECULES
#128KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY G MEMBER 1 (KLRG1) DEPLETING ANTIBODIES
#129Antibodies with Engineered O-Glycosylation Sequons for Site-Specific Conjugation
#130FC POLYPEPTIDE VARIANTS HAVING AN INCREASED HALF-LIFE
#131METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#132METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2
#133PERTUZUMAB VARIANTS AND EVALUATION THEREOF
#134THERAPEUTIC BINDING MOLECULES
#135FC-GAMMA RECEPTOR II BINDING AND GLYCAN CONTENT
#136BISPECIFIC BINDING PROTEINS AND USES THEREOF
#137Humanized and Affinity-Matured Anti-CEACAM1 Antibodies
#138BISPECIFIC ANTIBODIES AGAINST HER2
#139SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING
#140Methods for Producing Anti-TNF Antibody Compositions
#141STEROIDS AND ANTIBODY-CONJUGATES THEREOF
#142MONOVALENT INTERLEUKIN 12 (IL-12) HETERODIMERIC FC PROTEINS
#143POLYOMAVIRUS NEUTRALIZING ANTIBODIES
#144FC POLYPEPTIDE HAVING ALTERED GLYCOSYLATION MODIFICATION
#145METHODS AND MATERIALS FOR TREATING CANCER
#146COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES
#147ANTI-CCR8 ANTIBODIES AND USES THEREOF
#148Methods for Producing Anti-TNF Antibody Compositions
#149Manufacturing Methods for Producing Anti-TNF Antibody Compositions
#150ANTIBODIES AND METHODS OF USE
#151ANTIBODIES THAT RECOGNIZE RED BLOOD CELL ANTIGENS
#152Combination Therapies with Anti-CD38 Antibodies
#153BIOSYNTHETIC MONOVALENT BINDING MOLECULES WITH ENHANCED EFFECTOR FUNCTIONS
#154ANTI-B7H3 ANTIBODY AND USE THEREOF
#155COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH
#156PD-1/TIM-3 BINDING PROTEINS FOR TREATMENT OF NSCLC and cHL
#157HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE
#158AFLIBERCEPT ATTRIBUTES AND METHODS OF CHARACTERIZING AND MODIFYING THEREOF
#159ANTI-OX40 ANTIBODIES AND METHODS OF USE
#160OPTIMIZED CROSSLINKERS FOR TRAPPING A TARGET ON A SUBSTRATE
#161IgG EPITOPE AND APPLICATIONS THEREOF AS A DRUG TARGET
#162CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS
#163METHOD FOR PRODUCING AN ANTI-LAG-3 ANTIBODY
#164Anti-HBsAg antibody for treatment of chronic hepatitis D
#165IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOF
#166Site-Specific Crosslinking of Antibodies
#167RADIOLABELING OF POLYPEPTIDES
#168METHODS FOR SITE SPECIFIC CONJUGATION OF PROTEINS CONTAINING GLYCOSYLATED Fc DOMAINS
#169ANTIBODIES AGAINST CLEAVED CDCP1 AND USES THEREOF
#170DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
#171CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONS
#172ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF
#173TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER
#174ANTIBODY VARIANTS
#175TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES
#176STEROIDS AND ANTIBODY-CONJUGATES THEREOF
#177C3B INACTIVATING POLYPEPTIDE
#178Fc GLYCAN REMODELING PLATFORM METHOD FOR SITE-SPECIFIC ANTIBODY CONJUGATION AND APPLICATIONS THEREOF
#179MODULATION OF CELL GROWTH AND GLYCOSYLATION IN RECOMBINANT GLYCOPROTEIN PRODUCTION
#180ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF
#181INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
#182INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS
#183Epithelial Cadherin-Specific Antibodies
#184B7-H4 ANTIBODY DOSING REGIMENS
#185METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#186ANTI-CD25 ANTIBODY AGENTS
#187MODULATION OF ANTIBODY FUNCTION VIA SIALIC ACID MODIFICATION
#188ANTIGEN BINDING MOLECULES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
#189ANTIBODY MOLECULES
#190ANTI-CLDN6 AND ANTI-CD3 MULTISPECIFIC ANTIBODIES AND METHODS OF USE
#191CYTOTOXICITY-INDUCING THERAPEUTIC AGENT
#192PROCESS FOR IMPROVING POLYPEPTIDE EXPRESSION IN MAMMALIAN CELL CULTURE
#193USING FUCOSIDASE TO CONTROL AFUCOSYLATION LEVEL OF GLYCOSYLATED PROTEINS
#194Sialylated Glycoproteins
#195METHODS TO GLYCOENGINEER PROTEINS
#196ANTI-CXCR5 ANTIBODIES AND COMPOSITIONS AND USES THEREOF
#197ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE
#198Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
#199SITE-SPECIFIC ANTIBODY-DRUG GLYCONJUGATES AND METHODS
#200ANTI-CD20 ANTIBODY COMPOSITIONS
#201ENGINEERED ANTIBODY FC VARIANTS FOR ENHANCED SERUM HALF LIFE
#202ANTI-CD2 ANTIBODIES
#203NOVEL ANTIBODY FORMAT
#204HETERODIMERIC FC DOMAIN ANTIBODIES
#205CYTOTOXICITY-INDUCING THERAPEUTIC AGENT
#206Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
#207TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab
#208ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS
#209HYPERSIALYLATING CELLS
#210COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY
#211Antibody specific to spike protein of SARS-CoV-2 and uses thereof
#212CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN THERAPY
#213POLYPEPTIDE LINKER FOR PREPARING MULTISPECIFIC ANTIBODIES
#214HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF
#215ANTI-CD20 ANTIBODY COMPOSITIONS
#216ANTIBODIES AGAINST TIM3 AND USES THEREOF
#217METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS
#218ANTI-TSLP ANTIBODY COMPOSITIONS AND USES THEREOF
#219HYPERGLYCOSYLATED BINDING POLYPEPTIDES
#220Anti-CCR8 Antibodies and Uses Thereof
#221Sialylated Glycoproteins
#222METHODS OF MAKING FUCOSYLATED AND AFUCOSYLATED FORMS OF A PROTEIN
#223FAST PROTEIN SEQUENCING
#224Sialylated Glycoproteins
#225ANTI-INFLUENZA ANTIBODIES AND COMBINATIONS THEREOF
#226METHOD FOR MODULATING AFUCOSLYATION OF AN ANTIBODY PRODUCT
#227COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODY
#228SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES
#229BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS
#230IN VITRO GLYCOENGINEERING OF ANTIBODIES
#231ANTI-VIRAL THERAPEUTIC
#232VARIANT TARGET BINDING AGENTS AND USES THEREOF
#233DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODIES
#234DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODY
#235FAB SIALYLATION OF ANTIBODIES
#236THIOL VARIANTS AND ANALYTICAL METHODS THEREOF
#237SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES
#238ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF
#239MULTI-PARATOPIC ANTI-PD-1 ANTIBODIES AND USES THEREOF
#240MUSK ACTIVATION
#241Methods for Producing Fabs and IgG Bispecific Antibodies
#242NANOBODY-OGA FUSIONS AND USES THEREOF
#243RELATIVE UNPAIRED GLYCANS IN ANTIBODY PRODUCTION METHODS
#244CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT
#245Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering
#246Antibodies that target HIV GP120 and methods of use
#247COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
#248HUMAN IGE MONOCLONAL ANTIBODIES TO ANTIBODIES TO ALPHA-GAL (GALACTOSE-A-1,3-GALACTOSE) AND USES THEREFOR
#249ANTIBODIES AND METHODS OF USE
#250OPTIMIZED Fc VARIANTS
#251CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2
#252ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF
#253ANTIBODIES THAT BIND TO C-TYPE LECTIN DOMAIN FAMILY 2 MEMBER D (CLEC2D)
#254ANTI-PDL1 ANTIBODY FORMULATIONS
#255ANTI-PSMA ANTIBODIES AND METHODS OF USE
#256DOSING AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CTLA-4 ANTIBODY AS MONOTHERAPY
#257ANTI-L1-CAM ANTIBODIES AND USES THEREOF
#258FAB HIGH MANNOSE GLYCOFORMS
#259Systems and Methods for Diagnostic Assessment and Treatment of Insulin Resistance and Hyperglycemia
#260COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF
#261USE OF ANTI-OX40 ANTIBODY IN TREATMENT OF TUMOR OR CANCER
#262BISPECIFIC ANTIBODY BINDING TO CD3
#263BETA-1,4 GALACTOSYLATION OF PROTEINS
#264Polyomavirus neutralizing antibodies
#265Antibodies against TIM3 and uses thereof
#266COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOF
#267METHODS OF MAKING HYPER-SIALYLATED IMMUNOGLOBULIN
#268Anti-MUC1 antibody-drug conjugate
#269SIALYLATED GLYCOPROTEINS
#270ANTI-CD2 ANTIBODIES
#271HYPERSIALYLATED IMMUNOGLOBULIN
#272ENDO-S2 MUTANTS AS GLYCOSYNTHASES, METHOD OF MAKING AND USE FOR GLYCOENGINEERING OF GLYCOPROTEINS
#273BISPECIFIC MOLECULES BINDING TIGIT AND VEGF AND USES THEREOF
#274ANTIBODIES SPECIFIC FOR ALPHA-1,6-CORE-FUCOSYLATED PSA AND FUCOSYLATED FRAGMENTS THEREOF
#275OPTIMIZED ANTIBODIES THAT TARGET CD19
#276COMPOSITIONS AND METHODS FOR TREATING CANCER
#277Fc glycan remodeling platform method for site-specific antibody conjugation and applications thereof
#278Immune complex
#279METHODS AND COMPOSITIONS FOR TREATING SYSTEMIC MASTOCYTOSIS
#280METHODS RELATED TO BIOLOGICS
#281INERT FORMAT
#282Nucleic acids encoding, and methods of producing, antibodies that bind human chemokine (CāC motif) receptor 8 (CCR8)
#283Enzymes for Sialylation of Glycans
#284Fucosylation-deficient cells
#285IL1RAP BINDING PROTEINS
#286Anti-Inflammatory Polypeptides
#287Humanized monoclonal advanced glycation end-product antibody
#288ANTI-TREM2 ANTIBODIES AND RELATED METHODS
#289Production of biosimilar ustekinumab in CHO cells
#290ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF
#291ANTIBODIES TO CD70
#292ANTI-CTLA-4 BINDING PROTEINS AND METHODS OF USE THEREOF
#293FC MUTANTS WITH MODIFIED FUNCTIONAL ACTIVITY
#294Methods for increasing mannose content of recombinant proteins
#295Humanized antibodies against PSMA
#296DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES
#297ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF
#298HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
#299SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME
#300Anti-CD30 Antibodies and Methods for Treating CD30+ Cancer